Detection of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in vaginal swabs of women with acute SARS‐CoV‐2 infection: a prospective study

Objective To determine whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is present in the vagina of women diagnosed with coronavirus disease-19 (COVID-19) pneumonia. Study design The study was conducted prospectively in a university affiliated hospital. Forty-one women of reproductive age whose nasopharyngeal PCR test were positive for SARS-CoV-2 and clinically diagnosed with pneumonia were included in the study. Vaginal swabs were obtained for SARS-CoV-2 PCR tests when the patients were admitted to the inpatient service before pneumonia treatment was initiated. Results Vaginal swab samples of 38 patients were analysed with SARS-CoV-2 PCR tests. None of the vaginal swabs were positive for SARS-CoV-2. Conclusions SARS-CoV-2 does not infect the vagina of women diagnosed with SARS-CoV-2 pneumonia.

Download Full-text

Epistaxis as a marker for severe acute respiratory syndrome coronavirus-2 status – a prospective study

The Journal of Laryngology & Otology ◽

10.1017/s0022215120001863 ◽

2020 ◽

Vol 134 (8) ◽

pp. 717-720 ◽

Cited By ~ 1

Author(s):

MH Hussain ◽

M Mair ◽

P Rea

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Prospective Study ◽

Control Group ◽

Study Group ◽

Chain Reaction ◽

Polymerase Chain Reaction Testing ◽

The Mean ◽

Polymerase Chain ◽

The Difference ◽

A Prospective Study

AbstractObjectiveTo evaluate the prevalence of severe acute respiratory syndrome coronavirus-2 infection in patients presenting with epistaxis to a tertiary otolaryngology unit.MethodsA prospective study was conducted of 40 consecutive patients presenting with epistaxis referred to our tertiary otolaryngology unit. A group of 40 age-matched controls were also included. All patients underwent real-time reverse transcriptase polymerase chain reaction testing for severe acute respiratory syndrome coronavirus-2. Symptoms of fever, cough and anosmia were noted in the study group.ResultsThe mean age was 66.5 ± 22.4 years in the study group. There were 22 males (55 per cent) and 18 females (45 per cent). The mean age in the control group was 66.3 ± 22.4 years (p = 0.935). There were six positive cases for severe acute respiratory syndrome coronavirus-2 (15 per cent) in the epistaxis group and one case (2.5 per cent) in the control group. The difference was statistically significant (p = 0.05).ConclusionEpistaxis may represent a presenting symptom of severe acute respiratory syndrome coronavirus-2 infection. This may serve as a useful additional criterion for screening patients.

Download Full-text

Surgery Safety Protocol for Patients and Staff During the COVID-19 Global Pandemic – A Prospective Study of 78 Consecutive, Open and Laparoscopic Surgical Procedures

Surgical Case Reports ◽

10.31487/j.scr.2020.12.28 ◽

2020 ◽

pp. 1-6

Author(s):

Gianluca Matteo Sampietro ◽

Carlo Corbellini ◽

Caterina Baldi ◽

Salvatore Barberi ◽

...

Keyword(s):

Surgical Treatment ◽

Severe Acute Respiratory Syndrome ◽

Prospective Study ◽

Older Men ◽

Northern Italy ◽

Gas Filtration ◽

Global Pandemic ◽

Laparoscopic Surgical Procedures ◽

A Prospective Study ◽

Surgical Pathway

Background: To evaluate safety, for patients and staff, and efficacy of a protocol for the surgical treatment of patients during COVID-19 pandemic (50 days period) in a hospital located in the northern Italy. Methods: Two different pathways were adopted (non-COVID-19 and COVID-19), with dedicated OR and ICU, and PPE for personnel. A monitoring of patients and staff for COVID-19 was carried out. Results: 78 patients were included. Laparoscopy was used in 33.4% without gas filtration. COVID-19- positive patients (11.5%) were older men (0.04%), with elevated ASA score (0.002), and two or more comorbidities (0.02). They experienced longer hospitalization (0.003), more complications and more deaths (0.0001). All COVID-19 related deaths were due to severe acute respiratory syndrome. None of the patients included resulted infected, but one out of 47 staff personnel (<2%). Conclusion: COVID-19 is largely unknown, but a safe and effective surgical pathway is feasible.

Download Full-text

Evaluation of SARS-CoV-2 in the Vaginal Secretions of Women with COVID-19: A Prospective Study

Journal of Clinical Medicine ◽

10.3390/jcm10122735 ◽

2021 ◽

Vol 10 (12) ◽

pp. 2735

Author(s):

Elad Barber ◽

Michal Kovo ◽

Sophia Leytes ◽

Ron Sagiv ◽

Eran Weiner ◽

...

Keyword(s):

Polymerase Chain Reaction ◽

Severe Acute Respiratory Syndrome ◽

Medical Center ◽

Rt Pcr ◽

Chain Reaction ◽

Vaginal Colonization ◽

Vaginal Secretions ◽

Vaginal Swabs ◽

Polymerase Chain ◽

A Prospective Study

Objective: We aimed to investigate the likelihood of vaginal colonization with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pregnant and non-pregnant women with Coronavrus Disease 2019 (COVID-19). Materials and Methods: Vaginal swabs were taken from women diagnosed with mild to moderately acute SARS-CoV-2 infection, at Wolfson Medical Center, Israel, from March 2020 through October 2020. COVID-19 was diagnosed by real-time polymerase chain reaction (RT-PCR) performed on nasopharyngeal swabs. Vaginal swabs were tested for the presence of SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR). Results: In total, 51 women diagnosed with COVID-19 were included in the study. Of the 51 women with COVID-19 enrolled in this study, 16 (31.4%) were pregnant at enrollment and 35 (68.6%) were non-pregnant. Mean age was 43.5 ± 15.3 years (range 21–74 years). Compared to the non-pregnant group, the pregnant group was characterized by a higher white blood cell and absolute neutrophil count (p = 0.02 and p = 0.027, respectively). The non-pregnant patients were more likely to have chronic diseases (p = 0.035) and to be hospitalized (p < 0.001). Only one patient (1.9%) aged 60 years tested positive for SARS-CoV-2 in vaginal secretions. Mean gestational age at the diagnosis of COVID-19 of the pregnant group was 32.3 ± 7.8 weeks. Thirteen patients delivered during the study period; all delivered at term without obstetric complications and all neonates were healthy. Conclusions: Detection of SARS-CoV-2 in the vaginal secretions of patients diagnosed with COVID-19 is rare. Vaginal colonization may occur during the viremia phase of the disease, although infectivity from vaginal colonization needs to be proven.

Download Full-text

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study

10.1101/2020.07.20.20156398 ◽

2020 ◽

Cited By ~ 2

Author(s):

Michele Donato ◽

Steven Park ◽

Melissa Baker ◽

Robert Korngold ◽

Alison Morawski ◽

...

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Prospective Study ◽

Antiviral Therapy ◽

High Titer ◽

Laboratory Evaluation ◽

Respiratory Syndrome Virus ◽

Clinical Parameters ◽

A Prospective Study

Background Effective antiviral therapy against the severe acute respiratory syndrome virus 2 (SARS-CoV-2) remains elusive. Convalescent plasma is an anti-viral approach currently under investigation. We aimed to assess the laboratory and clinical parameters of patients with COVID-19 pneumonia treated with convalescent plasma containing high levels of neutralizing anti-SARS-CoV-2 antibodies.

Download Full-text

When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It

Journal of Clinical Medicine ◽

10.3390/jcm10020297 ◽

2021 ◽

Vol 10 (2) ◽

pp. 297

Author(s):

Stefano Cappanera ◽

Michele Palumbo ◽

Sherman H. Kwan ◽

Giulia Priante ◽

Lucia Assunta Martella ◽

...

Keyword(s):

Infectious Disease ◽

Severe Acute Respiratory Syndrome ◽

Prospective Study ◽

Cytokine Storm ◽

Cytokine Antagonists ◽

Infectious Disease Department ◽

The World ◽

Risk Of Progression ◽

Definition Of ◽

A Prospective Study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that is responsible for coronavirus disease 2019 (COVID-19), which has rapidly spread across the world, becoming a pandemic. The “cytokine storm” (CS) in COVID-19 leads to the worst stage of illness, and its timely control through immunomodulators, corticosteroids, and cytokine antagonists may be the key to reducing mortality. After reviewing published studies, we proposed a Cytokine Storm Score (CSs) to identify patients who were in this hyperinflammation state, and at risk of progression and poorer outcomes. We retrospectively analyzed 31 patients admitted to Infectious Disease Department in “St. Maria” Hospital in Terni with confirmed SARS-CoV-2 infections, and analyzed the “CS score” (CSs) and the severity of COVID-19. Then we conducted a prospective study of COVID-19 patients admitted after the definition of the CSscore. This is the first study that proposes and applies a new score to quickly identify COVID-19 patients who are in a hyperinflammation stage, to rapidly treat them in order to reduce the risk of intubation. CSs can accurately identify COVID-19 patients in the early stages of a CS, to conduct timely, safe, and effect administration of immunomodulators, corticosteroids, and cytokine antagonists, to prevent progression and reduce mortality.

Download Full-text